After Catalyst Case, FDA Won't Stop Approving Orphan Drugs
The U.S. Food and Drug Administration has said a loss in litigation involving a treatment for a rare autoimmune disease won't stop it from approving new orphan drugs if they have...To view the full article, register now.
Already a subscriber? Click here to view full article